Europe may delay transparency

Share this article:

The push for clinical trial transparency may be delayed. Pharmalot reports that the European Medicines Agency is wading through more than 1,000 comments supporting the initiative and vociferous attacks from the industry and its backers who claim the initiative will threaten patient safety and corporate intellectual property. Threats to pack up and take jobs elsewhere have also accompanied industry concerns.

The EMA planned on having data out in the open by January 2104. It will decide in December if this date is still possible.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.